Aviva PLC Sells 1,040 Shares of USANA Health Sciences, Inc. (NYSE:USNA)

Aviva PLC cut its stake in shares of USANA Health Sciences, Inc. (NYSE:USNA) by 6.2% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 15,777 shares of the company’s stock after selling 1,040 shares during the period. Aviva PLC’s holdings in USANA Health Sciences were worth $566,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of USNA. R Squared Ltd purchased a new stake in shares of USANA Health Sciences in the fourth quarter valued at about $28,000. KLP Kapitalforvaltning AS bought a new stake in USANA Health Sciences in the 4th quarter worth about $83,000. Quantbot Technologies LP purchased a new stake in USANA Health Sciences in the 4th quarter valued at about $132,000. Meeder Asset Management Inc. bought a new position in shares of USANA Health Sciences during the 4th quarter worth approximately $143,000. Finally, Amundi boosted its stake in shares of USANA Health Sciences by 85.3% in the 4th quarter. Amundi now owns 4,872 shares of the company’s stock worth $170,000 after buying an additional 2,243 shares during the last quarter. 54.25% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on USNA. DA Davidson decreased their price target on USANA Health Sciences from $38.00 to $36.00 and set a “neutral” rating for the company in a research report on Thursday, February 27th. Sidoti lowered USANA Health Sciences from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, February 18th. Finally, StockNews.com downgraded shares of USANA Health Sciences from a “strong-buy” rating to a “buy” rating in a report on Friday, February 14th.

Insiders Place Their Bets

In related news, insider Joshua Foukas sold 5,732 shares of the business’s stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $32.54, for a total transaction of $186,519.28. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Jim Brown sold 5,000 shares of the firm’s stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $29.47, for a total value of $147,350.00. Following the completion of the transaction, the chief executive officer now owns 15,716 shares of the company’s stock, valued at approximately $463,150.52. This represents a 24.14 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 15,920 shares of company stock worth $500,285 over the last quarter. 0.33% of the stock is currently owned by company insiders.

USANA Health Sciences Trading Down 1.9 %

USANA Health Sciences stock opened at $24.80 on Friday. The business’s 50 day simple moving average is $29.30 and its 200 day simple moving average is $34.10. USANA Health Sciences, Inc. has a 12 month low of $23.67 and a 12 month high of $49.78. The company has a market cap of $468.75 million, a price-to-earnings ratio of 8.76, a PEG ratio of 0.93 and a beta of 1.00.

USANA Health Sciences (NYSE:USNA) last issued its quarterly earnings results on Tuesday, February 25th. The company reported $0.64 EPS for the quarter, beating analysts’ consensus estimates of $0.49 by $0.15. USANA Health Sciences had a return on equity of 10.64% and a net margin of 6.30%. The firm had revenue of $213.61 million for the quarter, compared to analysts’ expectations of $208.82 million. As a group, equities research analysts forecast that USANA Health Sciences, Inc. will post 2.45 earnings per share for the current fiscal year.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.